4D Molecular Therapeutics, Inc. · Brief

Next report

9 days

Nov 9 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 8≥ implied

Feb 28 '25±71.1%▼−8.61%×0.12

May 8 '25±42.3%▼−4.94%×0.12

Aug 11 '25±76.3%▼−1.78%×0.02

Q3 FY25±11.6%▼−3.14%×0.27

Jan 7 '26±18.7%▲+8.07%×0.43

Q1 FY26±38.6%▲+4.91%×0.13

May 7 '26±34.6%▲+2.11%×0.06

Q2 FY26±30.9%▲+4.64%×0.15

quarterimplied−80%0+80%realized×

Q2 FY26±30.9%▲+4.64%×0.15

May '26±34.6%▲+2.11%×0.06

Q1 FY26±38.6%▲+4.91%×0.13

Jan '26±18.7%▲+8.07%×0.43

Q3 FY25±11.6%▼−3.14%×0.27

Aug '25±76.3%▼−1.78%×0.02

2 older reports

May '25±42.3%▼−4.94%×0.12

Feb '25±71.1%▼−8.61%×0.12

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 9 report · est.

Bull2 of 4

158managers reporting a position in the latest quarterly filings13F · Jun 30 '26

3 of 21of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

Bear2 of 4

4tracked funds holding FDMTN-PORT · Aug 31 '26

0.20%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

FDMT report session

No linked exposure.

Oct 26impliedImplied move: ±41.0% into Nov 9 earnings (Oct 26 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.